However, with the development of targeted therapies (such as BRAF, MEK, CDK4/6, and C-KIT inhibitors) and immunotherapies (including anti-CTLA4 antibodies and anti-PD-1 antibodies), the systemic treatment of melanoma has been dramatically revolutionized (20). This evidence concerns the gene MAP2K7 and melanoma.